Novavax is a few months away from results for its two lead vaccine programs — and it's taking steps “to enable us to launch our products as soon as possible post licensure,” CEO Stanley Erck said on a Wednesday earnings call.
SUBSCRIBE
Biohealth Innovation
Founding Member of
